» Articles » PMID: 39974639

A Comprehensive Review of Current Approaches in Bladder Cancer Treatment

Overview
Specialty Biochemistry
Date 2025 Feb 20
PMID 39974639
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer is one of the most common malignant tumors of the urinary system globally. It is also one of the most expensive cancers to manage, due to the need for extensive treatment and follow-ups that often involve invasive and costly procedures. Although there have been some improvements in treatment options, the quality of life they offer has not improved at the same rate as other cancers. Therefore, there is an urgent need to find new alternatives to ease the burden of bladder cancer on patients. Recent discoveries have opened new avenues for the diagnosis and management of bladder cancer even though the clinical approach has largely remained the same for years. The decline in bladder cancer-specific mortality in regions that promote social awareness of risk factors and reduction of carcinogenic exposure demonstrates the effectiveness of such measures. New agents have been approved for patients who have undergone radical cystectomy after Bacillus Calmette-Guérin failure. Current best practices for diagnosing and treating bladder cancer are presented in this review. The review discusses radiation therapy, photodynamic therapy, gene therapy, chemotherapy, and nanomedicine in relation to non muscle-invasive cancers and muscle-invasive bladder cancers, as well as systemic treatments.

References
1.
Sadikovic B, Al-Romaih K, Squire J, Zielenska M . Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2009; 9(6):394-408. PMC: 2691666. DOI: 10.2174/138920208785699580. View

2.
Frey B, Weiss E, Rubner Y, Wunderlich R, Ott O, Sauer R . Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012; 28(6):528-42. DOI: 10.3109/02656736.2012.677933. View

3.
Wen R, Umeano A, Chen P, Farooqi A . Polymer-Based Drug Delivery Systems for Cancer. Crit Rev Ther Drug Carrier Syst. 2018; 35(6):521-553. DOI: 10.1615/CritRevTherDrugCarrierSyst.2018021124. View

4.
Wang D, Jing Y, Ouyang S, Liu B, Zhu T, Niu H . Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents and . Oncol Lett. 2013; 6(5):1492-1498. PMC: 3813788. DOI: 10.3892/ol.2013.1565. View

5.
Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View